Document Classification

Section Type: RESULTS

Text: At week 24, reductions in HbA1c (mean baseline 7. 90-8. 02 % [62. 8-64. 1 mmol/mol]) with empagliflozin/linagliptin were superior to those with empagliflozin or linagliptin alone as add-on to metformin ; adjusted mean (SE) changes from baseline were -1. 19 % (0. 06) (-13. 1 mmol/mol [0. 7]) with empagliflozin 25 mg/linagliptin 5 mg, -1. 08 % (0. 06) (-11. 8 mmol/mol [0. 7]) with empagliflozin 10 mg/linagliptin 5 mg, -0. 62 % (0. 06) (-6. 8 mmol/mol [0. 7]) with empagliflozin 25 mg, -0. 66 % (0. 06) (-7. 2 mmol/mol [0. 7]) with empagliflozin 10 mg, and -0. 70 % (0. 06) (-7. 6 mmol/mol [0. 7]) with linagliptin 5 mg (P < 0. 001 for all comparisons).